Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases

Prostate Cancer Prostatic Dis. 2023 Dec;26(4):811. doi: 10.1038/s41391-023-00680-4.

Martin W Schoen^{1

2}, Kenneth R Carson³, Seth A Eisen^{4

5}, Charles L Bennett⁶, Suhong Luo⁵, Melissa A Reimers⁵, Eric M Knoche^{4

5}, Alison L Whitmer⁴, Yan Yan⁷, Bettina F Drake⁷, Kristen M Sanfilippo^{4

5}

¹ Saint Louis Veterans Affairs Medical Center, Saint Louis, MO, USA. martin.schoen@health.slu.edu.
² Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO, USA. martin.schoen@health.slu.edu.
³ Rush University, Chicago, IL, USA.
⁴ Saint Louis Veterans Affairs Medical Center, Saint Louis, MO, USA.
⁵ Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
⁶ University of South Carolina College of Pharmacy, Columbia, SC, USA.
⁷ Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.

No abstract available

Publication types